Neurochondrin Antibody, Cell-Binding Assay, Spinal Fluid
Use
Evaluating neurochondrin-IgG by cell-binding assay using spinal fluid from patients presenting with cerebellar and brainstem syndrome. Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration. Patients positive for neurochondrin-IgG present with a subacute to chronic cerebellar and brainstem syndrome and may respond to long-term immunosuppressive treatment.
Special Instructions
Not provided.
Limitations
A negative result does not exclude neurological autoimmunity or cancer. Although a positive result supports a diagnosis of central nervous system autoimmunity, the presence of neurochondrin antibodies may not definitively indicate a specific condition. Patients with different neurological conditions might exhibit overlapping antibody profiles, leading to potential diagnostic complexity.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
Neurochondrin
Protein
LOINC Codes
- 101449-7 - Neurochondrin Ab CSF Ql CBA IFA
- 101449-7 - Neurochondrin Ab CSF Ql CBA IFA
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
1.5 mL
Minimum Volume
Not provided
Container
Sterile vial
Collection Instructions
Only orderable as a reflex.
Causes for Rejection
Gross hemolysis, Gross lipemia, Gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |